Related Experiment Video
Updated: Sep 9, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Decoding PRTFDC1's Role in Lung Adenocarcinoma: From Gene Expression to Clinical Implications
Jian Yao1, Qiang Zhang1, Chunhe Zhong1
1Department of Thoracic Surgery, Jilin Provincial People's Hospital, Changchun, 130021, Jilin Province, China.
Introduction:
This study aims to elucidate the role of Phosphoribosyl Transferase Domain Containing 1 (PRTFDC1) in Lung Adenocarcinoma (LUAD) through bioinformatics analysis and experimental validation, exploring its potential as a biomarker for prognosis and treatment response.
Methods:
We analyzed PRTFDC1 gene expression patterns in 539 LUAD and 59 normal lung tissue samples from The Cancer Genome Atlas (TCGA). Using bioinformatics tools, we examined the correlation between PRTFDC1 expression and clinical characteristics, immune infiltration, Tumor Mutation Burden (TMB), and drug responsiveness. Experimental validation was conducted in LUAD cell lines (A549 and HCC-78) through the overexpression of PRTFDC1, followed by cell proliferation and cell cycle assays.
Results:
PRTFDC1 expression was significantly elevated in LUAD compared to normal tissues, correlating with poorer Progression-Free Survival (PFS) and Disease-Specific Survival (DSS). PRTFDC1 was associated with immune cell infiltration, TMB, and mRNA stemness index (mRNAsi). Overexpression of PRTFDC1 in LUAD cell lines promoted cell proliferation and cell cycle progression, mediated by Threonine Tyrosine Kinase (TTK).
Discussion:
The findings suggest that PRTFDC1 may serve as an independent prognostic marker for LUAD, influencing tumor progression and immune response. The correlation with TTK indicates a potential mechanism for PRTFDC1's impact on cell proliferation. However, further research is needed to validate these findings in larger cohorts and explore the underlying molecular mechanisms.
Conclusion:
PRTFDC1 is a promising biomarker for LUAD prognosis and treatment response, with potential implications for targeted therapies and personalized medicine.
